Generics Bulletin is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Teva Xtampza Settlement Brings Potential Three-Year Head Start

Suit In Delaware Court Settled With 2033 Date

Executive Summary

Teva is lining up another complex ANDA product after agreeing to settle litigation with Collegium Pharmaceutical over the Israeli firm’s proposed generic version of Xtampza ER (oxycodone) extended-release capsules.

You may also be interested in...



Teva Still Hopes To Reach Deal On US Price-Fixing Allegations

Teva says it remains hopeful that it can resolve US price-fixing allegations “in a positive way” with the US Department of Justice, but acknowledges that the matter could go all the way to trial.

US FDA Releases Slew Of Guidances On A Fell Day For Complex Generics

New and updated guidances are good news for ANDA sponsors, but timing – coming the day Sandoz announced a CRL for its Advair copy – underscores challenges that developers of complex generics face.

American Regent’s Vasopressin Questioned As Eagle Prepares ANDA Launch

With Eagle set to launch its long-awaited vasopressin ANDA product on 17 January, the US firm’s management told investors it was unsure what its launch meant for the 505(b)(2) rival product in the hands of American Regent.

Topics

Related Companies

UsernamePublicRestriction

Register

GB150326

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel